当前位置： SCI文献检索 > Drug Metabolism and Pharmacokinetics期刊下所有文献 > Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes.

Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes.

Abstract：

:The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated. Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline. CYP1A2 and CYP3A4 also contributed to the metabolism of selegiline but their catalytic activities were much less than that of CYP2B6. CYP2B6 had a higher affinity for both N-depropagylation (K(m)=21.4 microM) and N-demethylation (K(m)=25.2 microM) of selegiline than CYP3A4 and CYP1A2. In immunoinhibition studies using mixed human hepatic microsomes, selegiline N-depropagylation activity was most strongly inhibited by anti-CYP2B and anti-CYP3A antibodies, while selegiline N-demethylation activity was most inhibited by anti-CYP2B antibody. In CYP2B6-rich human hepatic microsomes, anti-CYP2B antibody had the strongest inhibitory effects on both activities. Selegiline inhibited CYP2B6-mediated (S)-mephenytoin N-demethylation activity and CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation activity. These findings suggest that attention should be paid to the drug-drug interaction associated with CYP2B6 and CYP2C19. In conclusion, CYP2B6 participates in the metabolism of selegiline but the degree of its contribution varies with the level of its expression in human liver.

journal_name

Drug Metab Pharmacokinet

journal_title

Drug metabolism and pharmacokinetics

authors

Kamada T,Chow T,Hiroi T,Imaoka S,Morimoto K,Ohde H,Funae Y

doi

10.2133/dmpk.17.199

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

199-206

issue

3

eissn

1347-4367

issn

1880-0920

pii

JST.JSTAGE/dmpk/17.199

journal_volume

17

pub_type

杂志文章

相关文献

Drug Metabolism and Pharmacokinetics文献大全
  • Synthesis and evaluation of nevirapine analogs to study the metabolic activation of nevirapine.

    abstract：:Nevirapine (NVP) is widely used as a non-nucleoside reverse transcriptase inhibitor of HIV-1, however, it is associated with severe skin and liver injury. The mechanisms of these adverse reactions are not yet clear, but the metabolic activation of NVP is thought to be related to the injury process. Until now, several ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.01.006

    authors： Tateishi Y,Ohe T,Yasuda D,Takahashi K,Nakamura S,Kazuki Y,Mashino T

    更新日期：2020-04-01 00:00:00

  • In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.

    abstract：:Since porphyrins are regarded as endogenous substrates for the ATP-binding cassette (ABC) transporter ABCG2, it is hypothesized that functional impairment owing to genetic polymorphisms or inhibition of ABCG2 by drugs may result in a disruption of cellular porphyrin homeostasis. In the present study, we expressed ABCG...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.22.428

    authors： Tamura A,Onishi Y,An R,Koshiba S,Wakabayashi K,Hoshijima K,Priebe W,Yoshida T,Kometani S,Matsubara T,Mikuriya K,Ishikawa T

    更新日期：2007-12-01 00:00:00

  • Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.

    abstract：:3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is a ring-substituted amphetamine widely used for recreational purposes. MDMA is predominantly O-demethylenated in humans by cytochrome P450 (CYP) 2D6, and is also a potent mechanism-based inhibitor of the enzyme. After assessing the inhibition and recovery of CYP2D6 i...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-12-rg-032

    authors： Yubero-Lahoz S,Pardo R,Farre M,Mathuna BÓ,Torrens M,Mustata C,Perez-Mañá C,Langohr K,Carbó ML,de la Torre R

    更新日期：2012-01-01 00:00:00

  • A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates.

    abstract：:The current EMA drug interaction guideline was published in 2012. This guideline gives important recommendations on the information required to elucidate the interaction potential of an investigational drug, both as effects of the investigational drug on the PK of other drugs and effects of other medicinal products on...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2019.11.005

    authors： Cole S,Kerwash E,Andersson A

    更新日期：2020-02-01 00:00:00

  • Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.

    abstract：:In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.08.006

    authors： Hikino K,Fukunaga K,Mushiroda T

    更新日期：2018-12-01 00:00:00

  • New SRM data dependent exclusion (MS)n measurement for structural determination of drug metabolites using LC/ESI/Ion trap MS.

    abstract：:New SRM (selected reaction monitoring) data dependent exclusion (MS)(n) measurement makes it possible to obtain MS(3) fragmentation data for all MS(2) fragments, useful for structural determination of drug metabolites using ESI ion trap. MS(2) fragments are produced by cleavage of all protonated molecules at the lone ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.18.390

    authors： Tozuka Z,Kaneko H,Shiraga T,Beppu M,Niwa T,Kawamura A,Kagayama A

    更新日期：2003-01-01 00:00:00

  • Five novel single nucleotide polymorphisms in the EPHX1 gene encoding microsomal epoxide hydrolase.

    abstract：:Five novel single nucleotide polymorphisms (SNPs) were found in the EPHX1 gene from 96 Japanese epileptic patients. The detected SNPs were as follows: 1) SNP, MPJ6_EX1009; GENE NAME, EPHX1 ACCESSION NUMBER, NT_004525.12; LENGTH, 25 bases; 5'-CCTCACTTCAGTG/ACTGGGCTTTGCC-3'. 2) SNP, MPJ6_EX1013; GENE NAME, EPHX1; ACCESS...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.18.150

    authors： Shiseki K,Itoda M,Saito Y,Nakajima Y,Maekawa K,Kimura H,Goto Y,Saitoh O,Katoh M,Ohnuma T,Kawai M,Sugai K,Ohtsuki T,Suzuki C,Minami N,Ozawa S,Sawada J

    更新日期：2003-01-01 00:00:00

  • Valproic acid transport in the choriocarcinoma placenta cell line JEG-3 proceeds independently of the proton-dependent transporters MCT1 and MCT4.

    abstract：:Medication therapy is the first line of treatment in the management of epilepsy. Fetal exposure to valproic acid (VPA), an antiepileptic drug, poses an elevated risk of teratogenicity in early pregnancy. Some studies have reported that monocarboxylate transporters (MCTs) may be involved in the placental transport of V...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.03.004

    authors： Ishiguro Y,Furugen A,Narumi K,Nishimura A,Hirano T,Kobayashi M,Iseki K

    更新日期：2018-12-01 00:00:00

  • Pharmacokinetics and bioavailability of tuftsin-derived T peptide, a promising antitumor agent, in beagles.

    abstract：:Tuftsin, a natural phagocytosis-stimulating tetrapeptide, had aroused much interest in tumor immunotherapy, but the poor pharmacokinetics hampered its clinical developments, for that it was extremely susceptible to degradation by enzymolysis in vivo. T Peptide (TP) was a newly designed tuftsin derivative aimed to enha...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.08.005

    authors： Gu R,He Y,Han S,Yuan S,An Y,Meng Z,Zhu X,Gan H,Wu Z,Li J,Zheng Y,Zhang L,Gao L,Dou G

    更新日期：2016-02-01 00:00:00

  • Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques.

    abstract：:Polymorphic human flavin-containing monooxygenase (FMO) 3 is an important drug-metabolizing enzyme for nitrogen- or sulfur-containing compounds. Cynomolgus macaques, a non-human primate species widely used in drug metabolism studies, have corresponding FMO3 molecular and enzymatic similarities to humans; however, gene...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.09.001

    authors： Uno Y,Shimizu M,Yoda H,Origuchi Y,Yamazaki H

    更新日期：2019-02-01 00:00:00

  • The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells.

    abstract：:Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2018.04.002

    authors： Terashima J,Jimma Y,Jimma K,Hakata S,Yachi M,Habano W,Ozawa S

    更新日期：2018-08-01 00:00:00

  • Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

    abstract：:The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concen...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.23.456

    authors： Ohno T,Nakade S,Nakayama K,Kitagawa J,Miyabe H,Konomi T,Miyata Y

    更新日期：2008-01-01 00:00:00

  • Involvement of moesin in the development of morphine analgesic tolerance through P-glycoprotein at the blood-brain barrier.

    abstract：:Altered expression of P-glycoprotein (P-gp), a drug efflux transporter expressed by brain capillary endothelial cells (BCECs), may contribute to the development of opioid analgesic tolerance, as demonstrated by cumulative evidence from research. However, the detailed mechanism by which chronic morphine treatment incre...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.DMPK-14-RG-042

    authors： Kobori T,Fujiwara S,Miyagi K,Harada S,Nakamoto K,Nakagawa T,Takahashi H,Narita M,Tokuyama S

    更新日期：2014-01-01 00:00:00

  • Methotrexate influx via folate transporters into alveolar epithelial cell line A549.

    abstract：:Methotrexate (MTX), a drug used for the treatment of certain cancers as well as rheumatoid arthritis, sometimes induces serious interstitial lung injury. Although lung toxicity of MTX is related to its accumulation, the information concerning MTX transport in the lungs is lacking. In this study, we investigated the me...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.04.005

    authors： Kawami M,Miyamoto M,Yumoto R,Takano M

    更新日期：2015-08-01 00:00:00

  • Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.

    abstract：:The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were assessed after exposure to NO-1886 and rifampicin, a typical inducer of CYP3As. mRNA levels were analyzed by real-time RT-PCR using an ABI PRISM 7700 Sequence Detector system. Exposure to NO-1886...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.21.19

    authors： Morioka Y,Nishimura M,Imai T,Suzuki S,Harada M,Satoh T,Naito S

    更新日期：2006-02-01 00:00:00

  • Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects.

    abstract：:Trimethylaminuria is caused by excessive malodorous trimethylamine excreted via urine and body secretion by decreased hepatic flavin-containing monooxygenase 3 (FMO3) metabolic capacity for transforming non-odorous trimethylamine N-oxide. This study investigates foodstuff first in healthy volunteers for palliative car...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.24.549

    authors： Shimizu M,Kozono M,Murayama N,Yamazaki H

    更新日期：2009-01-01 00:00:00

  • Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

    abstract：:Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolis...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2018.11.002

    authors： Glassman PM,Balthasar JP

    更新日期：2019-02-01 00:00:00

  • Effect of protein binding of pilsicainide on the pharmacokinetics.

    abstract：:To evaluate the effect of protein binding of pilsicainide on its clearance and the contribution of protein binding to optimized pilsicainide therapy, clinical laboratory and pharmacokinetic data were studied in 160 Japanese inpatients (Study 1) and 18 Japanese inpatients (Study 2). To determine the relation between pr...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.20.183

    authors： Fukumoto K,Tanemura M,Tsuchishita Y,Kusumoto M,Matsumoto K,Kamakura S,Ueno K

    更新日期：2005-06-01 00:00:00

  • Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.

    abstract：:In drug discovery, the cerebrospinal fluid (CSF) drug concentration (CCSF) has been used as a surrogate for the interstitial fluid (ISF) concentration (CISF). However, the CCSF-to-CISF gradient suggested for P-glycoprotein (P-gp) substrates in rodents causes uncertainty in CISF estimations and subsequent pharmacokinet...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.10.003

    authors： Nagaya Y,Nozaki Y,Takenaka O,Watari R,Kusano K,Yoshimura T,Kusuhara H

    更新日期：2016-02-01 00:00:00

  • Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24.

    abstract：:Human OATP2B1, a member of organic anion transporting polypeptide family, is expressed in several tissues, including small intestine and liver, and contributes to cellular uptake of endogenous compounds and various drugs. Altered expression of OATP2B1 affects pharmacokinetics of substrate drugs; however, limited infor...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2020.07.007

    authors： Liu W,Nakano M,Nakanishi T,Nakajima M,Tamai I

    更新日期：2020-12-01 00:00:00

  • The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.

    abstract：:Bioavailability and therapeutic outcome of treatment with HIV-protease inhibitors depends on intestinal and hepatic transporter-enzyme interplay. Liver transport of HIV protease inhibitors (saquinavir, darunavir) was assessed in the presence of aged garlic extract, because the HIV-infected often consume garlic supplem...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.25.307

    authors： Berginc K,Trontelj J,Kristl A

    更新日期：2010-01-01 00:00:00

  • Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.

    abstract：:Chemotherapy-induced neutropenia is one of the major adverse events which results in the reduction of chemotherapy. Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. We evaluated th...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2014.09.009

    authors： Ikeda M,Tsuji D,Yamamoto K,Kim YI,Daimon T,Iwabe Y,Hatori M,Makuta R,Hayashi H,Inoue K,Nakamichi H,Shiokawa M,Itoh K

    更新日期：2015-04-01 00:00:00

  • Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy.

    abstract：:Aldehyde oxidase contributes to drug metabolism and pharmacokinetics (PK), and a few clinical studies were discontinued because of aldehyde oxidase metabolism. Its AOX1, AOX3, AOX3L1, and AOX4 isoforms are expressed in mammals, and species differences in expression profiles reflect differences in drug metabolism and P...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1016/j.dmpk.2014.10.009

    authors： Sanoh S,Tayama Y,Sugihara K,Kitamura S,Ohta S

    更新日期：2015-02-01 00:00:00

  • CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers.

    abstract：:Cytochrome P450 2A6 (CYP2A6) is an enzyme involved in the metabolism of tobacco carcinogens, which are important risk factors in lung cancer. We and others have previously reported that CYP2A6*4, a whole-gene deletion polymorphism, is associated with lower risk of lung cancer than the wild-type allele. However, the ge...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.1016/j.dmpk.2015.04.002

    authors： Hosono H,Kumondai M,Arai T,Sugimura H,Sasaki T,Hirasawa N,Hiratsuka M

    更新日期：2015-08-01 00:00:00

  • Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes.

    abstract：:The enzyme activities of CYP2D6 and CYP2C19 show a genetic polymorphism, and the frequency of poor metabolizers (PMs) on these enzymes depends on races. We have analyzed frequencies of mutant alleles and PMs based on the published data in previous study (Shimizu, T. et al.: Bioinformatics research on inter-racial diff...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.18.71

    authors： Shimizu T,Ochiai H,Asell F,Yokono Y,Kikuchi Y,Nitta M,Hama Y,Yamaguchi S,Hashimoto M,Taki K,Nakata K,Aida Y,Ohashi A,Ozawa N

    更新日期：2003-01-01 00:00:00

  • Estimation of in vivo percutaneous absorption of emedastine from bile excretion data using a deconvolution method.

    abstract：:In vivo percutaneous absorption of emedastine difumarate was investigated in rats and compared with rat skin in vitro. Since emedastine entering the systemic circulation is mostly excreted in bile, we first came up with the method of collecting bile with a minimal skin incision. In vivo skin permeation of the drug was...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.20.331

    authors： Harada S,Yamashita F,Hashida M

    更新日期：2005-10-01 00:00:00

  • Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex.

    abstract：:The interaction between cytochrome P450s (CYP, P450) and UDP-glucuronosyltransferases (UGTs) was studied by co-immunoprecipitation. P450 isoform-selective antibody was used as a probe to co-precipitate UGTs with the P450s from solubilized rat liver microsomes. Antibodies toward CYP3A2, CYP2B2, CYP2C11/13 and CYP1A2 co...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.22.367

    authors： Ishii Y,Iwanaga M,Nishimura Y,Takeda S,Ikushiro S,Nagata K,Yamazoe Y,Mackenzie PI,Yamada H

    更新日期：2007-10-01 00:00:00

  • Emerging new technology: QSAR analysis and MO Calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP).

    abstract：:Protein kinases are potential drug targets for the treatment of a variety of diseases, including cancer. In particular, specific tyrosine kinase inhibitors are rapidly being developed as new drugs for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed tyrosine kinase inhibi...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2133/dmpk.25.72

    authors： Saito H,An R,Hirano H,Ishikawa T

    更新日期：2010-01-01 00:00:00

  • Evaluation of blood-brain barrier transporters by co-culture of brain capillary endothelial cells with astrocytes.

    abstract：:To investigate the transport function of the blood-brain barrier (BBB), we employed an in vitro model of the BBB, consisting of a co-culture of porcine brain capillary endothelial cells (BCECs) with rat astrocytes. Porcine BCECs were cultured on a filter insert with rat astrocytes on the underlying plastic well. Rat a...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.17.34

    authors： Kido Y,Tamai I,Nakanishi T,Kagami T,Hirosawa I,Sai Y,Tsuji A

    更新日期：2002-01-01 00:00:00

  • Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.

    abstract：:  Human cytochrome P450 CYP2A6 and CYP2A13 catalyze nicotine metabolisms and mediate activation of tobacco-specific carcinogens including 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). In this study, we found rhinacanthins A, B, and C isolated from Rhinac...

    journal_title：Drug metabolism and pharmacokinetics

    pub_type： 杂志文章

    doi：10.2133/dmpk.dmpk-13-rg-048

    authors： Pouyfung P,Prasopthum A,Sarapusit S,Srisook E,Rongnoparut P

    更新日期：2014-01-01 00:00:00